Correspondence 1799 blot analysis. However, examples of pure ALL cells contains no or few if any, expression of the MPO gene, indicating that MPO could be the best marker of myeloid differentiation. In this case, no TCR and immunoglobulin-heavy and -light chain rearrangements were detected by Southern blot analysis. We thus report here a case of AML-M0 complicated with generalized granulocytic sarcoma, as confirmed by in situ hybridization (ISH) for the detection of MPO gene expression.
TO THE EDITOR
Primary malignant disorders of basophils, ie acute basophilic leukemia, are rare. 1 However, basophilia may accompany other hematologic malignancies. Bone marrow and peripheral blood basophilia commonly accompanies chronic myelogenous leukemia (CML) and is an important diagnostic feature of this disease. 2 In those patients who present with accelerated disease or in blast crisis, the presence of basophilia is useful in distinguishing an underlying CML from de novo acute myeloid leukemia (AML). Basophilia is uncommonly associated with acute leukemia. Increased numbers of basophils occur in some cases AML containing either the t(6;9)(p23;q34) or chromosome 12p abnormalities. 3, 4 In this report, we describe an unusual case of AML containing a cryptic t(8;21) involving the AML1 and ETO genes that was associated with marked bone marrow basophilia. To our knowledge, this represents the first reported association of marked basophilia with expression of the chimeric AML1-ETO protein.
The patient, a 3.8-year-old white female, presented to her local pediatrician with a 2-day history of fever and sore throat. A complete blood count revealed a normal white blood count, hemoglobin of 5 g/dl and a platelet count of 16 × 10 9 /l. She was referred to the local pediatric oncology center where she received transfusions and underwent a diagnostic work-up, including bone marrow aspirates. The impression was that of acute leukemia, possibly representing blast crisis of CML. Following transfer to our institution, she was noted on physical examination to have petechiae and molluscum contagiosum lesions. At the time the bone marrow aspirate and biopsy were obtained, she developed hives wherever she was touched, and dermatographia was detected. Peripheral blood analysis revealed a white /l, a hematocrit of 32%, with a differential of 32% neutrophils, 1% band forms, 1% myelocytes, 38% blasts, 26% lymphocytes, 1% monocytes, and 1% basophils, and a platelet count of 64 × 10 9 /l. Examination of peripheral blood revealed 38% myeloblasts, some containing Auer rods (Figure 1a ). Bone marrow aspirate smears were hypercellular and contained frequent blasts, with occasional cells containing Auer rods (Figure 1c) . Remarkably, 26% of nucleated cells in the bone marrow were basophils, at various stages of maturation (Figure 1c) . Although the preponderance of the leukemic blasts had myeloblastic features, rare blasts were identified that contained distinct basophilic granules (not shown). Flow cytometric studies revealed that the blasts expressed CD33, CD13, CD15, CD65, CD11b, CD34 and cytoplasmic myeloperoxidase; a subset of the blasts also coexpressed CD19. RT-PCR analysis was performed on RNA extracted from the patient's bone marrow and was strongly positive for the expression of AML1-ETO chimeric transcripts (Figure 1b) . Conventional cytogenetic analysis revealed 46, XX, add(21)(q22). Fluorescence in situ hybridization (FISH) using a probe set for AML1-ETO (Spectrumorange-Spectrumgreen; Vysis, Downers Grove, IL, USA) was performed to evaluate the presence of a cryptic t(8;21). A fused AML1-ETO signal was observed on the der(21), indicating a cryptic insertion of a part of ETO into the AML1 locus. The expected reciprocal fusion signal on der(8) was not observed (Figure 1d ). The ETO signal, which should be on 8q22, was observed on 8qter, indicating that an inversion of the bands (8q22q24.3) possibly occurred prior to the gene rearrangement. In addition, FISH using whole chromosome painting probes for chromosomes 8 (biotin-labeled; Cambio, Cambridge, UK) and 21 (digoxigenin-labeled; Ventana Medical Systems, Tucson, AZ, USA) identified a cryptic insertion of chromosome 8 DNA material on chromosome 21, suggesting that the AML1-ETO gene rearrangement resulted from an insertion of part of the ETO gene into the AML1 locus (data not shown).
The patient received induction chemotherapy consisting of cytarabine and cladribine for AML with rapid clearance of myeloblasts from The fusion signal (yellow) was observed on the der(21) and no reciprocal fusion signal was observed on the der(8q). The remaining part of the ETO gene was located near the der(8q) terminal suggesting an inversion of the bands 8q22q24.3.
her bone marrow. The degree of basophilia has decreased in the 5 months since the patient initially presented; however, it is still present. The patient's most recent bone marrow aspirate was consistent with morphologic remission, although it contained 5% basophils; RT-PCR analysis performed on the same specimen was weakly positive for AML1-ETO transcript (data not shown). Interestingly, the patient's dermatographia has resolved concurrent with the reduction in bone marrow basophilia.
In addition to typical French-American-British (FAB)-M2 morphology, the presence of the t(8;21) in AML has been associated with the presence of several distinctive cytologic features. These include blasts with prominent Auer rods and intense MPO positivity, large salmon-colored cytoplasmic granules, and bone marrow eosinophilia. 5 In addition to eosinophilia, other hematologic abnormalities have occasionally been observed in AMLs containing the t(8;21) chromosomal translocation. For example, Kohli et al 6 described a patient with t(8;21)-associated AML who had marked leukocytosis and numerous immature myeloid forms in the peripheral blood, mimicking CML. Basophilia has not been described in association with AML with the t(8;21). The present case was characterized by the presence of marked bone marrow basophilia, a finding that raised the possibility of blast crisis of an underlying chronic myelogenous leukemia. It is uncertain whether this case represents an acute leukemia with basophilic differentiation or whether the basophilia is reactive, possibly secondary to the synthesis by the leukemic blasts of a factor that promotes the growth and differentiation of basophils. We attempted to perform FISH to determine whether the basophils contained the t(8;21) chromosomal translocation; however, these studies were difficult to interpret due to autofluorescence emitted by the basophilic granules (data not shown). RT-PCR analysis performed on a remission bone marrow aspirate that contained 5% basophils was only weakly positive for the t(8;21), suggesting that the latter interpretation may be correct.
In summary, we have presented an unusual case of AML with a cryptic t(8;21) that was associated with striking bone marrow basophilia. This case is significant as it broadens the spectrum of morphologic findings seen in t(8;21)-associated AML and illustrates the importance of cytogenetic and molecular diagnostic analyses in the evaluation of AML, particularly those with unusual morphologic features. Charities (ALSAC) of St Jude Children's Research Hospital. Since rising levels of disease can be demonstrated in bone marrow prior to clinical relapse, 4,5 we decided to determine whether rising levels could likewise be detected in the blood by PCR and whether the features of such molecular relapse in blood were such as to suggest that monitoring of blood may be of practical value. If answers to these questions were in the affirmative, then this would indicate that more extensive prospective studies of the value of monitoring of blood could well be important.
RB Lorsbach
Eight patients with B-lineage acute lymphoblastic leukemia (ALL) were selected who had a relapse involving marrow, the same monoclonal immunoglobulin heavy chain (IgH) or T cell receptor chain (TCR␥) gene rearrangement which was present at diagnosis and relapse and for which quantification was technically possible, and at least one blood sample adequate for study which had been obtained within the 6 months prior to relapse. MRD was quantified by PCR as previously described 6,7 and the absolute number of leukemic cells per liter of blood was calculated by multiplying together the leukocyte count and the relative MRD level. The eight patients comprised three children, two adolescents and three adults; six were studied during the period prior to the first relapse and two during the period prior to the second relapse. MRD was detected prior to relapse in all of the eight patients and the results are shown in Figure 1 . Levels of leukemia were 10 4 -10 6 cells/liter when first detected and rose to approximately 10 9 -10 11 cells/liter at relapse. In seven of the eight patients the number of leukemic cells increased approximately exponentially during the 8-10 weeks prior to relapse. Approximate doubling times were between 1.6 and 5.2 days. The eighth patient had a level of approximately 3 × 10 8 blasts/liter at clinical relapse and a similar value in the single pre-relapse sample available several weeks beforehand. MRD was detected in all patients at least 10 weeks prior to relapse and in one patient 24 weeks prior to relapse.
For seven of the eight patients the level of leukemia at the time of detection of molecular relapse was approximately five orders of magnitude less than the level at the time of clinical relapse. This would suggest that in these patients the total body burden of leukemic cells at the time of molecular relapse was correspondingly lower. For ALL at diagnosis it is known that the total number of leukemic cells present, as estimated from levels of blasts in the blood, is an important determinant of cure by chemotherapy. Detection of molecular relapse, when the body burden of leukemia is low, may enable treatment to be instituted at this time and it may be more effective than treatment instituted at the time of clinical relapse. Leukemia was also detected at a substantial time prior to clinical relapse. Our ability to detect leukemia at an early time was limited by size and availability of samples but, nevertheless, in the four patients with the longest series of samples, leukemia was detected at 19, 21, 23 and 24 weeks prior to relapse. With respect to treatment, this observation suggests that molecular relapse can be identified sufficiently early so that there is time to either confirm detection or demonstrate a rising level of leukemia, so that treatment can be instituted in a timely fashion. Careful attention to sample volume and timing might enable even earlier detection of molecular relapse and at a lower level of MRD.
With the exception of one patient, for whom there was only one sample available prior to relapse, the MRD levels showed a fairly rapid rate of increase in the 4-6 weeks prior to relapse. Approximate doubling times ranged from 1.6 to 5.2 days, with a median of 2-3 days. This rate of increase is much greater than that which can be inferred for childhood leukemia prior to diagnosis, 8 but it is similar to the rate of increase observed in marrow for childhood leukemia relapsing during treatment. 5 It seems likely that leukemia at relapse represents a rapidly growing subclone which, by extrapolation, in our patients had arisen approximately 5 months previously.
We previously reported data suggesting that the leukemic population at diagnosis consists of a major subpopulation which is drugsensitive and a minor subpopulation which is relatively drug-resistant. 9 We speculated that for patients destined to relapse, the critical mutations responsible for the phenotype of complete drug resistance most often occurred prior to diagnosis and led to the presence of a completely resistant clone within the larger relatively drug-resistant subpopulation. Nevertheless, irrespective of when the completely resistant clone arises, the cells which comprise it will persist and undergo further mutation, epimutation and selection during subsequent treatment, largely owing to the mutagenic and selective effects of chemotherapy. One can predict that this would lead to repeated clonal succession and the final emergence of a rapidly expanding clone, as was observed in the present study. If detection of molecular relapse in blood eventually proves to require detection of the ultimate rapidly-expanding clone, then, for practical reasons related to sampling and confirmation, the interval between confirmed molecular relapse and overt clinical relapse may be brief and, the knowledge that molecular relapse is present may be of little clinical value. On the other hand, if confirmation of molecular relapse can be based on the detection of slowly expanding earlier clones, then the interval may be much longer and clinically useful information may be obtained.
This study is, of course, only the first step in determining the utility of monitoring MRD in peripheral blood in order to detect molecular relapse. The next step will involve one or more large prospective studies, aimed at determining the general feasibility of the use of blood in a variety of patient subsets and at determining clinical outcomes, both in patients in whom the level of MRD is rising and in patients in whom MRD either is not detected or appears to be stable. Since
